Article
Immunology
Ariel Kenig, Yuval Ishay, Fadi Kharouf, Limor Rubin
Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.
CLINICAL IMMUNOLOGY
(2021)
Review
Immunology
Anna Furlan, Gabriella Forner, Ludovica Cipriani, Elisa Vian, Roberto Rigoli, Filippo Gherlinzoni, Piergiorgio Scotton
Summary: The study demonstrates significant effects of B cell-depleting agents on adaptive immunity, which should be considered in the selection of SARS-CoV-2 diagnostics and guiding therapeutic approaches. Combination therapeutic strategies may play a crucial role in the setting of B cell immune deficiencies.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Infectious Diseases
Wenyan Zhu, Tiange Xie, Mengru Xu, Ruxuan Chen, Ting Zhang
Summary: This case report presents a patient with prolonged SARS-CoV-2 infection, who had undergone B-cell depletion therapy. The patient responded well to the combination treatment of antiviral medication, convalescent plasma, and corticosteroid. It highlights the importance of recognizing the possibility of persistent SARS-CoV-2 infection in immunocompromised individuals, particularly when migratory pulmonary infiltrates are detected on chest CT.
INFECTION AND DRUG RESISTANCE
(2023)
Article
Immunology
Jo Linda Sinagra, Claudio Vedovelli, Raffaella Binazzi, Adele Salemme, Francesco Moro, Cinzia Mazzanti, Biagio Didona, Giovanni Di Zenzo
Summary: Managing patients with chronic autoimmune diseases during the COVID-19 pandemic is challenging due to the risks associated with the conditions themselves and drug-induced immunosuppression. In the case of pemphigus patients, immunosuppressant therapies like rituximab can pose a risk of increased susceptibility to infections, despite being highly effective treatments.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Urology & Nephrology
Alexandre Fillon, Benedicte Sautenet, Christelle Barbet, Lea Moret, Eve Marie Thillard, Annie Pierre Jonville-Bera, Jean Michel Halimi
Summary: Five cases of severe necrotizing vasculitis following SARS-CoV-2 RNA-based vaccine were described, including four cases of relapsing ANCA vasculitis and one case of de novo PAN in a patient with quiescent chronic hepatitis B. Ten additional cases were reported in the French national pharmacovigilance database, with six patients having ANCA-associated vasculitis and four patients having PAN (with first symptoms occurring on average 19 days after vaccination). Five of these 10 patients developed kidney dysfunction. In conclusion, COVID-19 vaccines may be associated with de novo or recurrent ANCA vasculitis or PAN, and attention should be given to patients with known ANCA vasculitis or a history of hepatitis B infection.
CLINICAL KIDNEY JOURNAL
(2022)
Article
Oncology
Gianpaolo Marcacci, Giuseppe Fiorentino, Francesco Volzone, Umberto Falcone, Roberto Parrella, Daniela Donnarumma, Silvia D'Ovidio, Anna Annunziata, Giovanni Micallo, Giuseppe Portella, Annarosaria De Chiara, Rosaria De Filippi, Stefania Crisci, Antonio Pinto
Summary: Patients with non-hodgkin lymphomas may exhibit unique dynamics in COVID-19 due to their disease-related immunodeficiencies, requiring regular molecular and antibody testing, as well as personalized treatment strategies.
INFECTIOUS AGENTS AND CANCER
(2021)
Article
Engineering, Electrical & Electronic
Sudarshan Nandy, Mainak Adhikari
Summary: The outbreak of the coronavirus is growing due to the lack of standard diagnosis. An intelligent model is needed to monitor patient health remotely and predict abnormalities quickly for more efficient diagnosis and treatment.
IEEE SENSORS JOURNAL
(2021)
Article
Hematology
Yair Herishanu, Irit Avivi, Anat Aharon, Gabi Shefer, Shai Levi, Yotam Bronstein, Miguel Morales, Tomer Ziv, Yamit Shorer Arbel, Lydia Scarfo, Erel Joffe, Chava Perry, Paolo Ghia
Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.
Article
Multidisciplinary Sciences
Jun Sugihara, Sho Shibata, Masafumi Doi, Takuya Shimmura, Shinichiro Inoue, Osamu Matsumoto, Hiroyuki Suzuki, Ayaka Makino, Yasunari Miyazaki
Summary: Atypical lymphocytes frequently appeared in the peripheral blood of COVID-19 patients one week after disease onset, with a higher likelihood of pneumonia and oxygen treatment. However, approximately two-thirds of patients with atypical lymphocytes showed clinical improvement after their appearance.
Article
Immunology
Martina Fabris, Ginevra De Marchi, Rossana Domenis, Federica Caponnetto, Silvia Guella, Chiara Dal Secco, Nicola Cabas, Salvatore De Vita, Antonio Paolo Beltrami, Francesco Curcio, Luca Quartuccio
Summary: This study evaluated the immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases who were previously treated with or under continuous treatment with B-cell-targeted therapies. The results showed that even in the absence of circulating B cells, virus-specific cellular immunity can be induced, indicating that B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Medicine, General & Internal
Stanislaw Lacki, Kinga Wyzgolik, Michal Nicze, Sylwia Georgiew-Nadziakiewicz, Jerzy Chudek, Kamil Wdowiak
Summary: This case study demonstrates that rituximab-based immunotherapy for follicular lymphoma may not have evident negative effects on the clinical course of COVID-19. The patient successfully completed the chemotherapy regimen and achieved complete remission without significant deterioration after being diagnosed with mild COVID-19 during ongoing oncological treatment.
WORLD JOURNAL OF CLINICAL CASES
(2021)
Article
Virology
Naohiro Aida, Taihei Ito, Kei Kurihara, Izumi Hiratsuka, Megumi Shibata, Atsushi Suzuki, Midori Hasegawa, Takashi Kenmochi
Summary: Kidney transplant recipients on immunosuppressive therapy are at high risk for COVID-19. This study investigated the effect of B cell depletion therapy on COVID-19 in 30 kidney transplant recipients. Results showed that patients receiving B cell depletion therapy had higher progression rates and lower survival rates compared to those without the therapy, suggesting an increased risk of COVID-19 in kidney transplant recipients due to long-term effects of B cell depletion therapy.
Article
Clinical Neurology
Annette Langer-Gould, Jessica B. Smith, Bonnie H. Li, Brandon E. Beaber, Sonu M. Brara, Julie Debacker, Allen Scott Nielsen, Samira Amirova, Oluwasheyi Ayeni
Summary: Rituximab-treated persons with multiple sclerosis (pwMS) have a higher likelihood of hospitalization but not death from COVID-19 compared to the non-MS population. Factors like time in months and receiving higher doses at last infusion are independent predictors of COVID-19 severity. Therefore, caution should be taken in dose and interval selection during treatment.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
(2021)
Article
Immunology
Romy N. Bouwmeester, Esther M. G. Bormans, Caroline Duineveld, Arjan D. van Zuilen, Anne-Els van de Logt, Jack F. M. Wetzels, Nicole C. A. J. van de Kar
Summary: COVID-19 vaccination has been associated with the development of atypical hemolytic uremic syndrome (aHUS) in some patients, but the overall risk is limited. It is recommended to continue vaccination in patients with a previous episode of aHUS, with clear instructions on how to recognize symptoms of recurrence.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Rheumatology
Samuel Bitoun, Julien Henry, Delphine Desjardins, Christelle Vauloup-Fellous, Nicolas Dib, Rakiba Belkhir, Lina Mouna, Candie Joly, Marie Bitu, Bineta Ly, Juliette Pascaud, Raphaele Seror, Anne-Marie Roque Afonso, Roger Le Grand, Xavier Mariette
Summary: The antibody response to the mRNA COVID-19 vaccine is diminished in patients treated with rituximab (RTX), but the functional T cell response remains unchanged compared to patients treated with other immunosuppressants and healthy controls.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
Walter P. Maksymowych, Nele Herregods, Nisha Varma, Arthur B. Meyers, Jennifer Stimec, Andrea S. Doria, Nikolay Tzaribachev, Tarimobo M. Otobo, Marion A. van Rossum, Joel Paschke, Stephanie Wichuk, Robert G. Lambert
Summary: This study aimed to investigate whether systematic calibration improves the scoring proficiency of JAMRIS-SIJ and whether contrast-enhancement enhances its performance. The results showed that calibrated readers achieved greater reliability in scoring specific inflammatory and structural lesions. Sensitivity and reliability for scoring inflammatory lesions were higher on fluid-sensitive sequences compared to contrast-enhanced sequences. Therefore, systematic calibration should be implemented before using JAMRIS-SIJ in clinical trials, and it is unlikely that contrast-enhanced MRI will improve the performance of this method.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2024)
Article
Rheumatology
L. van Ouwerkerk, S. A. Bergstra, T. D. Maarseveen, T. W. J. Huizinga, R. Knevel, C. F. Allaart
Summary: This study evaluated whether the initial use of glucocorticoid (GC) bridging in RA patients leads to a higher probability of long-term GC and bDMARD use. The results showed that patients who initially started GC had a higher risk of later GC use, but the risk of bDMARD use was not significantly increased.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2024)
Article
Rheumatology
ShuangHua Liu, YiMei Tan, WeiDong Huang, HongSheng Luo, BingCheng Pan, Shuan Wu
Summary: This study assessed the cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis. The results showed that in women with primary osteoporosis, zoledronic acid may increase the risk of atrial fibrillation and arrhythmias, but the cardiovascular risk in men with osteoporosis is uncertain.
SEMINARS IN ARTHRITIS AND RHEUMATISM
(2024)
